Captrust Financial Advisors Halozyme Therapeutics, Inc. Transaction History

Captrust Financial Advisors

$38.8 Billion
Q1 2025

A detailed history of Captrust Financial Advisors transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 34,575 shares of HALO stock, worth $1.88 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

34,575

Previous 29,862 15.78%

Holding current value

$1.88 Million

Previous $1.43 Million 54.59%

% of portfolio

0.01%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$47.74 - $65.16 $224,998 - $307,099	4,713 Added 15.78%	34,575 $2.21 Million
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $248,140 - $356,093	5,829 Added 24.25%	29,862 $1.43 Million
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $119,529 - $150,098	-2,330 Reduced 8.84%	24,033 $1.37 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $14,443 - $20,016	-382 Reduced 1.43%	26,363 $1.38 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $23,946 - $29,826	-711 Reduced 2.59%	26,745 $1.09 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $35,085 - $44,331	1,053 Added 3.99%	27,456 $1.01 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $962,653 - $1.16 Million	26,403 New	26,403 $1.01 Million
Q4 2022 Feb 15, 2023	BUY	$40.06 - $59.44 $184,516 - $273,780	4,606 New	4,606 $262,000
Q2 2022 Aug 16, 2022	BUY	$37.35 - $48.3 $19,720 - $25,502	528 Added 15.65%	3,902 $172,000
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $4,060 - $5,214	127 Added 3.91%	3,374 $135,000
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $11,105 - $14,221	349 Added 12.04%	3,247 $131,000
Q3 2021 Nov 16, 2021	BUY	$38.47 - $46.42 $12,041 - $14,529	313 Added 12.11%	2,898 $118,000
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $116 - $153	-3 Reduced 0.12%	2,585 $117,000
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $25,009 - $32,567	633 Added 32.38%	2,588 $108,000
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $6,581 - $11,123	255 Added 15.0%	1,955 $83,000
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $27,625 - $45,577	1,700 New	1,700 $47,000
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $25,381 - $33,201	-1,700 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$16.68 - $18.41 $28,356 - $31,297	1,700 New	1,700 $31,000

Others Institutions Holding HALO

# of Institutions

594

Shares Held

124M

Call Options Held

320K

Put Options Held

113K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Halozyme Therapeutics, Inc. Transaction History